Alembic Pharmaceuticals (BOM:533573) Cyclically Adjusted Revenue per Share: ₹324.74 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:533573 Alembic Pharmaceuticals Ltd BOM:533573
87 GF Score
Price ₹825.10
GF Value ₹1,101.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alembic Pharmaceuticals Cyclically Adjusted Revenue per Share?

Alembic Pharmaceuticals BOM:533573 +0.27% 87 Cyclically Adjusted Revenue per Share is ₹324.74 as of Jun. 2026. GuruFocus rates BOM:533573 with a GF Score™ of 87/100 and a GF Value™ of ₹1,101.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Alembic Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹109.308. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹324.74 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Alembic Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Alembic Pharmaceuticals was 10.60% per year. The lowest was 9.20% per year. And the median was 9.90% per year.

As of today (2026-08-18), Alembic Pharmaceuticals's current stock price is ₹825.10. Alembic Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹324.74. Alembic Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 2.54.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alembic Pharmaceuticals was 4.50. The lowest was 2.01. And the median was 3.09.


Alembic Pharmaceuticals  (BOM:533573) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alembic Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=825.10/324.74
=2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Alembic Pharmaceuticals was 4.50. The lowest was 2.01. And the median was 3.09.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Alembic Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Alembic Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Alembic Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alembic Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Alembic Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.24 243.03 268.27 292.63 316.33

Alembic Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 300.60 306.60 310.31 316.33 324.74

BOM:533573 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alembic Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alembic Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:533573
87GF Score
Alembic Pharmaceuticals Ltd BOM:533573
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alembic Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alembic Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=109.308/167.3573*167.3573
=109.308

Current CPI (Jun. 2026) = 167.3573.

Alembic Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 46.675 105.961 73.720
201612 41.208 105.196 65.558
201703 39.362 105.196 62.621
201706 34.417 107.109 53.777
201709 41.880 109.021 64.289
201712 44.574 109.404 68.186
201803 45.309 109.786 69.069
201806 45.763 111.317 68.802
201809 59.770 115.142 86.875
201812 54.016 115.142 78.512
201903 42.381 118.202 60.005
201906 50.314 120.880 69.659
201909 65.805 123.175 89.409
201912 64.125 126.235 85.014
202003 57.978 124.705 77.808
202006 71.146 127.000 93.754
202009 75.353 130.118 96.919
202012 66.846 130.889 85.471
202103 59.199 131.771 75.187
202106 67.462 134.084 84.203
202109 65.723 135.847 80.968
202112 64.699 138.161 78.371
202203 68.238 138.822 82.265
202206 64.180 142.347 75.456
202209 74.995 144.661 86.761
202212 76.738 145.763 88.107
202303 63.678 146.865 72.563
202306 75.663 150.280 84.261
202309 81.171 151.492 89.672
202312 82.952 152.924 90.781
202403 71.277 153.035 77.948
202406 79.298 155.789 85.186
202409 83.683 157.882 88.705
202412 85.725 158.323 90.617
202503 90.010 157.552 95.612
202506 86.988 159.755 91.127
202509 97.209 162.289 100.245
202512 95.389 163.281 97.771
202603 93.981 164.272 95.746
202606 109.308 167.357 109.308

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹324.74 mean?
Alembic Pharmaceuticals (BOM:533573) has a Cyclically Adjusted Revenue per Share of ₹324.74 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alembic Pharmaceuticals and its competitors.
Is Alembic Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Alembic Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹324.74. Overall, Alembic Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Alembic Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹324.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Alembic Pharmaceuticals and its competitors. Alembic Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹324.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (BOM:533573) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,101.61, compared to a current price of ₹825.10 — trading 25.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹324.74. Alembic Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Alembic Pharmaceuticals (BOM:533573), the current Cyclically Adjusted Revenue per Share is ₹324.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alembic Pharmaceuticals (BOM:533573) Overvalued in 2026?

Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued. The current stock price of ₹825.10 is trading 25.1% below its estimated GF Value™ of ₹1,101.61. GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BOM:533573:

  • Cyclically Adjusted Revenue per Share: ₹324.74
  • GF Value™: ₹1,101.61 vs. price of ₹825.10 (25.1% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the BOM:533573 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alembic Pharmaceuticals Business Description

Other Exchanges APLLTD:India
Address Alembic Road, Vadodara, GJ, IND, 390 003
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
87GF Score

Get the complete analysis for BOM:533573

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹825.10
Price
₹1,101.61
GF Value